Principles and mechanisms of CD95 activation

Biological Chemistry

Volumn 395, Issue 12, 2014, Pages 1401-1416

  Wajant, Harald ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Acidic sphingomyelinase; Apoptosis; Caspase 8; CD95 (Apo1 Fas); CD95L; Lipid raft

Indexed keywords

ACTIN; APOPTOSIS INDUCING FACTOR; FAS ANTIGEN; FAS LIGAND;

ACTIN FILAMENT; APOPTOSIS; CELL ACTIVATION; CONFERENCE PAPER; HUMAN; INTERNALIZATION; INTRACELLULAR SIGNALING; LIPID RAFT; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; ANIMAL; CELL MEMBRANE; CHEMISTRY; METABOLISM; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION;

ACTIN CYTOSKELETON; ANIMALS; ANTIGENS, CD95; APOPTOSIS; HUMANS; MEMBRANE MICRODOMAINS; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION;

EID: 84926364443     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2014-0212     Document Type: Conference Paper

References (123)

1. Algeciras-Schimnich, A. and Peter, M.E. (2003). Actin dependent CD95 internalization is specific for Type I cells. FEBS Lett. 546, 185-188.
2. Algeciras-Schimnich, A., Shen, L., Barnhart, B.C., Murmann, A.E., Burkhardt, J.K., and Peter, M.E. (2002). Molecular ordering of the initial signaling events of CD95. Mol. Cell. Biol. 22, 207-220.
3. Aoki, K., Kurooka, M., Chen, J.J., Petryniak, J., Nabel, E.G., and Nabel, G.J. (2001). Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity. Nat. Immunol. 2, 333-337.
4. Bajorath, J. (1999). Analysis of Fas-ligand interactions using a molecular model of the receptor-ligand interface. J. Comput Aided Mol. Des. 13, 409-418.
5. Barnhart, B.C., Alappat, E.C., and Peter, M.E. (2003). The CD95 type I/type II model. Semin. Immunol. 15, 185-193.
6. Beneteau, M., Pizon, M., Chaigne-Delalande, B., Daburon, S., Moreau, P., De Giorgi, F., Ichas, F., Rebillard, A., Dimanche-Boitrel, M.T., Taupin, J.L., et al. (2008). Localization of Fas/CD95 into the lipid rafts on down-modulation of the phosphatidylinositol 3-kinase signaling pathway. Mol. Cancer Res. 6, 604-613.
7. Berg, D., Lehne, M., Muller, N., Siegmund, D., Munkel, S., Sebald, W., Pfizenmaier, K., and Wajant, H. (2007). Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death Differ. 14, 2021-2034.
8. Bodmer, J.L., Schneider, P., and Tschopp, J. (2002). The molecular architecture of the TNF superfamily. Trends Biochem. Sci. 27, 19-26.
9. Bremer, E., ten Cate, B., Samplonius, D.F., de Leij, L.F., and Helfrich, W. (2006). CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia. Blood 107, 2863-2870.
10. Bremer, E., ten Cate, B., Samplonius, D.F., Mueller, N., Wajant, H., Stel, A.J., Chamuleau, M., van de Loosdrecht, A.A., Stieglmaier, J., Fey, G.H., et al. (2008). Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists. Cancer Res. 68, 597-604.
11. Brint, E., O'Callaghan, G., and Houston, A. (2013). Life in the Fas lane: differential outcomes of Fas signaling. Cell. Mol. Life Sci. 70, 4085-4099.
12. Cahuzac, N., Baum, W., Kirkin, V., Conchonaud, F., Wawrezinieck, L., Marguet, D., Janssen, O., Zornig, M., and Hueber, A.O. (2006). Fas ligand is localized to membrane rafts, where it displays increased cell death-inducing activity. Blood 107, 2384-2391.
13. Celeste Morley, S., Sun, G.P., and Bierer, B.E. (2003). Inhibition of actin polymerization enhances commitment to and execution of apoptosis induced by withdrawal of trophic support. J. Cell. Biochem. 88, 1066-1076.
14. Chaigne-Delalande, B., Mahfouf, W., Daburon, S., Moreau, J.F., and Legembre, P. (2009). CD95 engagement mediates actin-independent and -dependent apoptotic signals. Cell Death Differ. 16, 1654-1664.
15. Chakrabandhu, K., Herincs, Z., Huault, S., Dost, B., Peng, L., Conchonaud, F., Marguet, D., He, H.T., and Hueber, A.O. (2007). Palmitoylation is required for efficient Fas cell death signaling. EMBO J. 26, 209-220.
16. Chakrabandhu, K., Huault, S., Garmy, N., Fantini, J., Stebe, E., Mailfert, S., Marguet, D., and Hueber, A.O. (2008). The extracellular glycosphingolipid-binding motif of Fas defines its internalization route, mode and outcome of signals upon activation by ligand. Cell Death Differ. 15, 1824-1837.
17. Chan, F.K. (2007). Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling. Cytokine 37, 101-107.
18. Cremesti, A., Paris, F., Grassme, H., Holler, N., Tschopp, J., Fuks, Z., Gulbins, E., and Kolesnick, R. (2001). Ceramide enables fas to cap and kill. J. Biol. Chem. 276, 23954-23961.
19. Degli Esposti, M., Tour, J., Ouasti, S., Ivanova, S., Matarrese, P., Malorni, W., and Khosravi-Far, R. (2009). Fas death receptor enhances endocytic membrane traffic converging into the Golgi region. Mol. Biol. Cell 20, 600-615.
20. Delmas, D., Rebe, C., Lacour, S., Filomenko, R., Athias, A., Gambert, P., Cherkaoui-Malki, M., Jannin, B., Dubrez-Daloz, L., Latruffe, N., et al. (2003). Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J. Biol. Chem 278, 41482-41490.
21. De Maria, R., Rippo, M.R., Schuchman, E.H., and Testi, R. (1998). Acidic sphingomyelinase (ASM) is necessary for fas-induced GD3 ganglioside accumulation and efficient apoptosis of lymphoid cells. J. Exp. Med 187, 897-902.
22. DeMorrow, S., Glaser, S., Francis, H., Venter, J., Vaculin, B., Vaculin, S., and Alpini, G. (2007). Opposing actions of endocannabinoids on cholangiocarcinoma growth: recruitment of Fas and Fas ligand to lipid rafts. J. Biol. Chem. 282, 13098-13113.
23. Desbarats, J., Birge, R.B., Mimouni-Rongy, M., Weinstein, D.E., Palerme, J.S., and Newell, M.K. (2003). Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat. Cell Biol. 5, 118-125.
24. Dhein, J., Daniel, P.T., Trauth, B.C., Oehm, A., Moller, P., and Krammer, P.H. (1992). Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J. Immunol. 149, 3166-3173.
25. Dickens, L.S., Boyd, R.S., Jukes-Jones, R., Hughes, M.A., Robinson, G.L., Fairall, L., Schwabe, J.W., Cain, K., and Macfarlane, M. (2012a). A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death. Mol. Cell 47, 291-305.
26. Dickens, L.S., Powley, I.R., Hughes, M.A., and MacFarlane, M. (2012b). The 'complexities' of life and death: death receptor signalling platforms. Exp. Cell Res. 318, 1269-1277.
27. Du, C., Fang, M., Li, Y., Li, L., and Wang, X. (2000). Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102, 33-42.
28. Edelmann, B., Bertsch, U., Tchikov, V., Winoto-Morbach, S., Perrotta, C., Jakob, M., Adam-Klages, S., Kabelitz, D., and Schütze, S. (2011). Caspase-8 and caspase-7 sequentially mediate proteolytic activation of acid sphingomyelinase in TNF-R1 receptosomes. EMBO J. 30, 379-394.
29. Ehrenschwender, M., Siegmund, D., Wicovsky, A., Kracht, M., Dittrich-Breiholz, O., Spindler, V., Waschke, J., Kalthoff, H., Trauzold, A., and Wajant, H. (2010). Mutant PIK3CA licenses TRAIL and CD95L to induce non-apoptotic caspase-8-mediated ROCK activation. Cell Death Differ. 17, 1435-1447.
30. Elyassaki, W. and Wu, S. (2006). Lipid rafts mediate ultraviolet light-induced Fas aggregation in M624 melanoma cells. Photochem. Photobiol. 82, 787-792.
31. Engels, I.H., Stepczynska, A., Stroh, C., Lauber, K., Berg, C., Schwenzer, R., Wajant, H., Janicke, R.U., Porter, A.G., Belka, C., et al. (2000). Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. Oncogene 19, 4563-4573.
32. Eramo, A., Sargiacomo, M., Ricci-Vitiani, L., Todaro, M., Stassi, G., Messina, C.G., Parolini, I., Lotti, F., Sette, G., Peschle, C., et al. (2004). CD95 death-inducing signaling complex formation and internalization occur in lipid rafts of type I and type II cells. Eur. J. Immunol. 34, 1930-1940.
33. Esposito, D., Sankar, A., Morgner, N., Robinson, C.V., Rittinger, K., and Driscoll, P.C. (2010). Solution NMR investigation of the CD95/FADD homotypic death domain complex suggests lack of engagement of the CD95 C-terminus. Structure 18, 1378-1390.
34. Fanzo, J.C., Lynch, M.P., Phee, H., Hyer, M., Cremesti, A., Grassme, H., Norris, J.S., Coggeshall, K.M., Rueda, B.R., Pernis, A.B., et al. (2003). CD95 rapidly clusters in cells of diverse origins. Cancer Biol. Ther. 2, 392-395.
35. Feig, C., Tchikov, V., Schutze, S., and Peter, M.E. (2007). Palmitoylation of CD95 facilitates formation of SDS-stable receptor aggregates that initiate apoptosis signaling. EMBO J. 26, 221-231.
36. Ferreira, K.S., Kreutz, C., Macnelly, S., Neubert, K., Haber, A., Bogyo, M., Timmer, J., and Borner, C. (2012). Caspase-3 feeds back on caspase-8, Bid and XIAP in type I Fas signaling in primary mouse hepatocytes. Apoptosis 17, 503-515.
37. Fumarola, C., Zerbini, A., and Guidotti, G.G. (2001). Glutamine deprivation-mediated cell shrinkage induces ligand-independent CD95 receptor signaling and apoptosis. Cell Death Differ. 8, 1004-1013.
38. Gajate, C. and Mollinedo, F. (2001). The antitumor ether lipid ET-18-OCH(3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood 98, 3860-3863.
39. Gajate, C. and Mollinedo, F. (2005). Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apopto-sis- promoting clusters in cancer chemotherapy. J. Biol. Chem. 280, 11641-11647.
40. Gajate, C. and Mollinedo, F. (2007). Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 109, 711-719.
41. Gajate, C., Fonteriz, R.I., Cabaner, C., Alvarez-Noves, G., Alvarez-Rodriguez, Y., Modolell, M., and Mollinedo, F. (2000). Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis. Int J. Cancer 85, 674-682.
42. Gillissen, B., Richter, A., Overkamp, T., Essmann, F., Hemmati, P.G., Preissner, R., Belka, C., and Daniel, P.T. (2013). Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent 'type I' mode. Cell Death Dis. 4, e643.
43. Grassme, H., Cremesti, A., Kolesnick, R., and Gulbins, E. (2003). Ceramide-mediated clustering is required for CD95-DISC formation. Oncogene 22, 5457-5470.
44. Guicciardi, M.E. and Gores, G.J. (2009). Life and death by death receptors. FASEB J. 23, 1625-1637.
45. Hebert, M., Potin, S., Sebbagh, M., Bertoglio, J., Breard, J., and Hamelin, J. (2008). Rho-ROCK-dependent ezrin-radixin-moesin phosphorylation regulates Fas-mediated apoptosis in Jurkat cells. J. Immunol. 181, 5963-5973.
46. Henkler, F., Behrle, E., Dennehy, K.M., Wicovsky, A., Peters, N., Warnke, C., Pfizenmaier, K., and Wajant, H. (2005). The extracellular domains of FasL and Fas are sufficient for the formation of supramolecular FasL-Fas clusters of high stability. J. Cell Biol. 168, 1087-1098.
47. Herrero, R., Kajikawa, O., Matute-Bello, G., Wang, Y., Hagimoto, N., Mongovin, S., Wong, V., Park, D.R., Brot, N., Heinecke, J.W., et al. (2011). The biological activity of FasL in human and mouse lungs is determined by the structure of its stalk region. J. Clin. Invest. 121, 1174-1190.
48. Holler, N., Zaru, R., Micheau, O., Thome, M., Attinger, A., Valitutti, S., Bodmer, J.L., Schneider, P., Seed, B., and Tschopp, J. (2000). Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat. Immunol. 1, 489-495.
49. Jodo, S., Kung, J.T., Xiao, S., Chan, D.V., Kobayashi, S., Tateno, M., Lafyatis, R., and Ju, S.T. (2003). Anti-CD95-induced lethality requires radioresistant FcγRII+ cells. A novel mechanism for fulminant hepatic failure. J. Biol. Chem. 278, 7553-7557.
50. Jost, P.J., Grabow, S., Gray, D., McKenzie, M.D., Nachbur, U., Huang, D.C., Bouillet, P., Thomas, H.E., Borner, C., Silke, J., et al. (2009). XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 460, 1035-1039.
51. Kamitani, T., Nguyen, H.P., and Yeh, E.T. (1997). Activation-induced aggregation and processing of the human Fas antigen. Detection with cytoplasmic domain-specific antibodies. J. Biol. Chem. 272, 22307-22314.
52. Kirkin, V., Cahuzac, N., Guardiola-Serrano, F., Huault, S., Luckerath, K., Friedmann, E., Novac, N., Wels, W.S., Martoglio, B., Hueber, A.O., et al. (2007). The Fas ligand intracellular domain is released by ADAM10 and SPPL2a cleavage in T-cells. Cell Death Differ. 14, 1678-1687.
53. Kirschnek, S., Paris, F., Weller, M., Grassme, H., Ferlinz, K., Riehle, A., Fuks, Z., Kolesnick, R., and Gulbins, E. (2000). CD95-mediated apoptosis in vivo involves acid sphingomyelinase. J. Biol. Chem. 275, 27316-27323.
54. Kischkel, F.C., Hellbardt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, P.H., and Peter, M.E. (1995). Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14, 5579-5588.
55. Kleber, S., Sancho-Martinez, I., Wiestler, B., Beisel, A., Gieffers, C., Hill, O., Thiemann, M., Mueller, W., Sykora, J., Kuhn, A., et al. (2008). Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 13, 235-248.
56. Kreuz, S., Siegmund, D., Rumpf, J.J., Samel, D., Leverkus, M., Janssen, O., Hacker, G., Dittrich-Breiholz, O., Kracht, M., Scheurich, P., et al. (2004). NF-κB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP. J. Cell Biol. 166, 369-380.
57. Kulms, D., Dussmann, H., Poppelmann, B., Stander, S., Schwarz, A., and Schwarz, T. (2002). Apoptosis induced by disruption of the actin cytoskeleton is mediated via activation of CD95 (Fas/ APO-1). Cell Death Differ. 9, 598-608.
58. Kuo, W.C., Yang, K.T., Hsieh, S.L., and Lai, M.Z. (2010). Ezrin is a negative regulator of death receptor-induced apoptosis. Oncogene 29, 1374-1383.
59. Lacour, S., Hammann, A., Grazide, S., Lagadic-Gossmann, D., Athias, A., Sergent, O., Laurent, G., Gambert, P., Solary, E., and Dimanche-Boitrel, M.T. (2004). Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res. 64, 3593-3598.
60. Lang, I., Fick, A., Schafer, V., Giner, T., Siegmund, D., and Wajant, H. (2012). Signaling active CD95 receptor molecules trigger cotranslocation of inactive CD95 molecules into lipid rafts. J. Biol. Chem. 287, 24026-24042.
61. Lee, K.H., Feig, C., Tchikov, V., Schickel, R., Hallas, C., Schutze, S., Peter, M.E., and Chan, A.C. (2006). The role of receptor internalization in CD95 signaling. EMBO J. 25, 1009-1023.
62. Legembre, P., Beneteau, M., Daburon, S., Moreau, J.F., and Taupin, J.L. (2003). Cutting edge: SDS-stable Fas microaggregates: an early event of Fas activation occurring with agonistic anti-Fas antibody but not with Fas ligand. J. Immunol. 171, 5659-5662.
63. Legembre, P., Daburon, S., Moreau, P., Moreau, J.F., and Taupin, J.L. (2006). Modulation of Fas-mediated apoptosis by lipid rafts in T lymphocytes. J. Immunol. 176, 716-720.
64. Leon-Bollotte, L., Subramaniam, S., Cauvard, O., Plenchette-Colas, S., Paul, C., Godard, C., Martinez-Ruiz, A., Legembre, P., Jeannin, J.F., and Bettaieb, A. (2011). S-nitrosylation of the death receptor fas promotes fas ligand-mediated apoptosis in cancer cells. Gastroenterology 140, 2009-2018, 2018, e2001-2004.
65. Lingwood, D. and Simons, K. (2010). Lipid rafts as a membrane-organizing principle. Science 327, 46-50.
66. Lozupone, F., Lugini, L., Matarrese, P., Luciani, F., Federici, C., Iessi, E., Margutti, P., Stassi, G., Malorni, W., and Fais, S. (2004). Identification and relevance of the CD95-binding domain in the N-terminal region of ezrin. J. Biol. Chem. 279, 9199-9207.
67. Luciani, F., Matarrese, P., Giammarioli, A.M., Lugini, L., Lozupone, F., Federici, C., Iessi, E., Malorni, W., and Fais, S. (2004). CD95/ phosphorylated ezrin association underlies HIV-1GP120/IL-2-induced susceptibility to CD95(APO-1/Fas)-mediated apoptosis of human resting CD4+ T lymphocytes. Cell Death Differ. 11, 574-582.
68. Malleter, M., Tauzin, S., Bessede, A., Castellano, R., Goubard, A., Godey, F., Leveque, J., Jezequel, P., Campion, L., Campone, M., et al. (2013). CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancer. Cancer Res. 73, 6711-6721.
69. Matarrese, P., Manganelli, V., Garofalo, T., Tinari, A., Gambardella, L., Ndebele, K., Khosravi-Far, R., Sorice, M., Esposti, M.D., and Malorni, W. (2008). Endosomal compartment contributes to the propagation of CD95/Fas-mediated signals in type II cells. Biochem. J. 413, 467-478.
70. Matsuno, H., Yudoh, K., Watanabe, Y., Nakazawa, F., Aono, H., and Kimura, T. (2001). Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand. J. Rheumatol. 28, 22-28.
71. Meng, Y., Kang, S., and Fishman, D.A. (2005). Lysophosphatidic acid inhibits anti-Fas-mediated apoptosis enhanced by actin depolymerization in epithelial ovarian cancer. FEBS Lett. 579, 1311-1319.
72. Micheau, O., Solary, E., Hammann, A., and Dimanche-Boitrel, M.T. (1999). Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J. Biol. Chem. 274, 7987-7992.
73. Mitsiades, N., Yu, W.H., Poulaki, V., Tsokos, M., and Stamenkovic, I. (2001). Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res. 61, 577-581.
74. Miyaji, M., Jin, Z.X., Yamaoka, S., Amakawa, R., Fukuhara, S., Sato, S.B., Kobayashi, T., Domae, N., Mimori, T., Bloom, E.T., et al. (2005). Role of membrane sphingomyelin and ceramide in platform formation for Fas-mediated apoptosis. J. Exp. Med. 202, 249-259.
75. Moretti, S., Procopio, A., Lazzarini, R., Rippo, M.R., Testa, R., Marra, M., Tamagnone, L., and Catalano, A. (2008). Semaphorin3A signaling controls Fas (CD95)-mediated apoptosis by promoting Fas translocation into lipid rafts. Blood 111, 2290-2299.
76. Muppidi, J.R. and Siegel, R.M. (2004). Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death. Nat. Immunol. 5, 182-189.
77. Nachbur, U., Kassahn, D., Yousefi, S., Legler, D.F., and Brunner, T. (2006). Posttranscriptional regulation of Fas (CD95) ligand killing activity by lipid rafts. Blood 107, 2790-2796.
78. Ndozangue-Touriguine, O., Sebbagh, M., Merino, D., Micheau, O., Bertoglio, J., and Breard, J. (2008). A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma. Oncogene 27, 6012-6022.
79. Papoff, G., Hausler, P., Eramo, A., Pagano, M.G., Di Leve, G., Signore, A., and Ruberti, G. (1999). Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor. J. Biol. Chem. 274, 38241-38250.
80. Paris, F., Grassme, H., Cremesti, A., Zager, J., Fong, Y., Haimovitz-Friedman, A., Fuks, Z., Gulbins, E., and Kolesnick, R. (2001). Natural ceramide reverses Fas resistance of acid sphingomyelinase-/- hepatocytes. J. Biol. Chem. 276, 8297-8305.
81. Park, M.A., Zhang, G., Martin, A.P., Hamed, H., Mitchell, C., Hylemon, P.B., Graf, M., Rahmani, M., Ryan, K., Liu, X., et al. (2008). Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol. Ther. 7, 1648-1662.
82. Park, M.A., Mitchell, C., Zhang, G., Yacoub, A., Allegood, J., Haussinger, D., Reinehr, R., Larner, A., Spiegel, S., Fisher, P.B., et al. (2010). Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca2+-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res. 70, 6313-6324.
83. Parlato, S., Giammarioli, A.M., Logozzi, M., Lozupone, F., Matarrese, P., Luciani, F., Falchi, M., Malorni, W., and Fais, S. (2000). CD95 (APO-1/Fas) linkage to the actin cytoskeleton through ezrin in human T lymphocytes: a novel regulatory mechanism of the CD95 apoptotic pathway. EMBO J. 19, 5123-5134.
84. Petrovas, C., Mueller, Y.M., Yang, G., Altork, S.R., Jacobson, J.M., Pitsakis, P.G., Mounzer, K.C., Altman, J.D., and Katsikis, P.D. (2007). Actin integrity is indispensable for CD95/Fas-induced apoptosis of HIV-specific CD8+ T cells. Apoptosis 12, 2175-2186.
85. Pizon, M., Rampanarivo, H., Tauzin, S., Chaigne-Delalande, B., Daburon, S., Castroviejo, M., Moreau, P., Moreau, J.F., and Legembre, P. (2011). Actin-independent exclusion of CD95 by PI3K/AKT signalling: implications for apoptosis. Eur. J. Immunol. 41, 2368-2378.
86. Rossin, A., Kral, R., Lounnas, N., Chakrabandhu, K., Mailfert, S., Marguet, D., and Hueber, A.O. (2010). Identification of a lysinerich region of Fas as a raft nanodomain targeting signal necessary for Fas-mediated cell death. Exp. Cell Res. 316, 1513-1522.
87. Ruan, W., Lee, C.T., and Desbarats, J. (2008). A novel juxtamembrane domain in tumor necrosis factor receptor superfamily molecules activates Rac1 and controls neurite growth. Mol. Biol. Cell 19, 3192-3202.
88. Samel, D., Muller, D., Gerspach, J., Assohou-Luty, C., Sass, G., Tiegs, G., Pfizenmaier, K., and Wajant, H. (2003). Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted activation. J. Biol. Chem. 278, 32077-32082.
89. Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K.J., Debatin, K.M., Krammer, P.H., and Peter, M.E. (1998). Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17, 1675-1687.
90. Schleich, K., Warnken, U., Fricker, N., Oztürk, S., Richter, P., Kammerer, K., Schnölzer, M., Krammer, P.H., and Lavrik, I.N. (2012). Stoichiometry of the CD95 death-inducing signaling complex: experimental and modeling evidence for a death effector domain chain model. Mol. Cell 47, 306-319.
91. Schneider, P., Bodmer, J.L., Holler, N., Mattmann, C., Scuderi, P., Terskikh, A., Peitsch, M.C., and Tschopp, J. (1997). Characterization of Fas (Apo-1, CD95)-Fas ligand interaction. J. Biol. Chem. 272, 18827-18833.
92. Schneider, P., Holler, N., Bodmer, J.L., Hahne, M., Frei, K., Fontana, A., and Tschopp, J. (1998). Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187, 1205-1213.
93. Schulte, M., Reiss, K., Lettau, M., Maretzky, T., Ludwig, A., Hartmann, D., de Strooper, B., Janssen, O., and Saftig, P. (2007). ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death. Cell Death Differ. 14, 1040-1049.
94. Sessler, T., Healy, S., Samali, A., and Szegezdi, E. (2013). Structural determinants of DISC function: new insights into death receptor-mediated apoptosis signalling. Pharmacol Ther. 140, 186-199.
95. Siegel, R.M., Martin, D.A., Zheng, L., Ng, S.Y., Bertin, J., Cohen, J., and Lenardo, M.J. (1998). Death-effector filaments: novel cytoplasmic structures that recruit caspases and trigger apoptosis. J. Cell Biol. 141, 1243-1253.
96. Siegel, R.M., Frederiksen, J.K., Zacharias, D.A., Chan, F.K., Johnson, M., Lynch, D., Tsien, R.Y., and Lenardo, M.J. (2000). Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 288, 2354-2357.
97. Siegel, R.M., Muppidi, J.R., Sarker, M., Lobito, A., Jen, M., Martin, D., Straus, S.E., and Lenardo, M.J. (2004). SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane. J. Cell Biol. 167, 735-744.
98. Siegmund, D., Wicovsky, A., Schmitz, I., Schulze-Osthoff, K., Kreuz, S., Leverkus, M., Dittrich-Breiholz, O., Kracht, M., and Wajant, H. (2005). Death receptor-induced signaling pathways are differentially regulated by gamma interferon upstream of caspase 8 processing. Mol. Cell. Biol. 25, 6363-6379.
99. Siegmund, D., Klose, S., Zhou, D., Baumann, B., Roder, C., Kalthoff, H., Wajant, H., and Trauzold, A. (2007). Role of caspases in CD95L- and TRAIL-induced non-apoptotic signalling in pancreatic tumour cells. Cell. Signal. 19, 1172-1184.
100. Soderstrom, T.S., Nyberg, S.D., and Eriksson, J.E. (2005). CD95 capping is ROCK-dependent and dispensable for apoptosis. J. Cell Sci. 118, 2211-2223.
101. Starling, G.C., Bajorath, J., Emswiler, J., Ledbetter, J.A., Aruffo, A., and Kiener, P.A. (1997). Identification of amino acid residues important for ligand binding to Fas. J. Exp. Med. 185, 1487-1492.
102. Stegh, A.H., Barnhart, B.C., Volkland, J., Algeciras-Schimnich, A., Ke, N., Reed, J.C., and Peter, M.E. (2002). Inactivation of caspase-8 on mitochondria of Bcl-xL-expressing MCF7-Fas cells: role for the bifunctional apoptosis regulator protein. J. Biol. Chem. 277, 4351-4360.
103. Stoicov, C., Cai, X., Li, H., Klucevsek, K., Carlson, J., Saffari, R., and Houghton, J. (2005). Major histocompatibility complex class II inhibits fas antigen-mediated gastric mucosal cell apoptosis through actin-dependent inhibition of receptor aggregation. Infect. Immun. 73, 6311-6321.
104. Stroh, C. and Schulze-Osthoff, K. (1998). Death by a thousand cuts: an ever increasing list of caspase substrates. Cell Death Differ. 5, 997-1000.
105. Subauste, M.C., Von Herrath, M., Benard, V., Chamberlain, C.E., Chuang, T.H., Chu, K., Bokoch, G.M., and Hahn, K.M. (2000). Rho family proteins modulate rapid apoptosis induced by cytotoxic T lymphocytes and Fas. J. Biol. Chem. 275, 9725-9733.
106. Suda, T., Tanaka, M., Miwa, K., and Nagata, S. (1996). Apoptosis of mouse naive T cells induced by recombinant soluble Fas ligand and activation-induced resistance to Fas ligand. J. Immunol. 157, 3918-3924.
107. Suda, T., Hashimoto, H., Tanaka, M., Ochi, T., and Nagata, S. (1997). Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 186, 2045-2050.
108. Tanaka, M., Suda, T., Takahashi, T., and Nagata, S. (1995). Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J. 14, 1129-1135.
109. Tanaka, M., Itai, T., Adachi, M., and Nagata, S. (1998). Downregulation of Fas ligand by shedding. Nat. Med. 4, 31-36.
110. Tauzin, S., Chaigne-Delalande, B., Selva, E., Khadra, N., Daburon, S., Contin-Bordes, C., Blanco, P., Le Seyec, J., Ducret, T., Counillon, L., et al. (2011). The naturally processed CD95L elicits a c-yes/calcium/PI3K-driven cell migration pathway. PLoS Biol. 9, e1001090.
111. Tauzin, S., Debure, L., Moreau, J.F., and Legembre, P. (2012). CD95-mediated cell signaling in cancer: mutations and post-translational modulations. Cell. Mol. Life Sci. 69, 1261-1277.
112. Thurau, M., Everett, H., Tapernoux, M., Tschopp, J., and Thome, M. (2006). The TRAF3-binding site of human molluscipox virus FLIP molecule MC159 is critical for its capacity to inhibit Fas-induced apoptosis. Cell Death Differ. 13, 1577-1585.
113. Tinsley, K.W., Herzog, D., and Leitenberg, D. (2011). CD4 co-receptor dependent signaling promotes competency for re-stimulation induced cell death of effector T cells. Cell. Immunol. 266, 200-207.
114. Vargo-Gogola, T., Crawford, H.C., Fingleton, B., and Matrisian, L.M. (2002). Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. Arch. Biochem. Biophys. 408, 155-161.
115. Verhagen, A.M., Ekert, P.G., Pakusch, M., Silke, J., Connolly, L.M., Reid, G.E., Moritz, R.L., Simpson, R.J., and Vaux, D.L. (2000). Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102, 43-53.
116. Vogler, M., Walczak, H., Stadel, D., Haas, T.L., Genze, F., Jovanovic, M., Gschwend, J.E., Simmet, T., Debatin, K.M., and Fulda, S. (2008). Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res. 68, 7956-7965.
117. Walker, T., Mitchell, C., Park, M.A., Yacoub, A., Rahmani, M., Haussinger, D., Reinehr, R., Voelkel-Johnson, C., Fisher, P.B., Grant, S., et al. (2010). 17-Allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species. Mol. Cancer Ther. 9, 1378-1395.
118. Wang, L., Yang, J.K., Kabaleeswaran, V., Rice, A.J., Cruz, A.C., Park, A.Y., Yin, Q., Damko, E., Jang, S.B., Raunser, S., et al. (2010). The Fas-FADD death domain complex structure reveals the basis of DISC assembly and disease mutations. Nat. Struct Mol. Biol. 17, 1324-1329.
119. Wilson, T.R., McEwan, M., McLaughlin, K., Le Clorennec, C., Allen, W.L., Fennell, D.A., Johnston, P.G., and Longley, D.B. (2009). Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells. Oncogene 28, 63-72.
120. Xu, Y., Szalai, A.J., Zhou, T., Zinn, K.R., Chaudhuri, T.R., Li, X., Koopman, W.J., and Kimberly, R.P. (2003). Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J. Immunol. 171, 562-568.
121. Xu, Z.X., Ding, T., Haridas, V., Connolly, F., and Gutterman, J.U. (2009). Avicin D, a plant triterpenoid, induces cell apoptosis by recruitment of Fas and downstream signaling molecules into lipid rafts. PLoS One 4, e8532.
122. Zhang, G., Park, M.A., Mitchell, C., Hamed, H., Rahmani, M., Martin, A.P., Curiel, D.T., Yacoub, A., Graf, M., Lee, R., et al. (2008). Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin. Cancer Res. 14, 5385-5399.
123. Zhuang, S. and Kochevar, I.E. (2003). Ultraviolet A radiation induces rapid apoptosis of human leukemia cells by Fas ligand-independent activation of the Fas death pathways. Photochem. Photobiol. 78, 61-67.